
Loading, please wait...

Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates

The prospective German NICO study provides vital real-world insights into melanoma brain metastasis treatment. This study evaluated the effectiveness and safety of nivolumab combined with ipilimumab versus nivolumab monotherapy in a large cohort of 755 patients. Importantly, the research includes patients often excluded from clinical trials, offering a realistic view of oncology practice. Consequently, the findings help clinicians understand how these immunotherapies perform in diverse patient populations, including those with challenging prognostic factors.
During the study, researchers observed that a significant proportion of patients achieved meaningful clinical benefits. Specifically, first-line treatment with the nivolumab and ipilimumab combination resulted in an objective response rate (ORR) of 46.2% in patients with brain involvement. In contrast, those receiving nivolumab alone in the first-line setting showed an ORR of 61.5%. Furthermore, the 3-year overall survival (OS) rates for the combination group reached 34%, while the monotherapy group reached 42.7%. These variations likely reflect baseline differences, as the combination group often included younger patients with more aggressive disease markers.
Notably, the presence of symptoms and the use of steroids significantly impacted patient outcomes. For instance, patients with asymptomatic brain metastases showed a 3-year OS rate of 42.2%. However, those with symptomatic disease requiring dexamethasone saw this rate drop to 20%. Therefore, early detection and treatment before the onset of neurologic symptoms remain critical goals in management. Moreover, a landmark analysis at three months showed that patients achieving a complete or partial response enjoyed excellent long-term survival. Specifically, responders on nivolumab alone achieved an 89.6% 3-year OS rate, while those on the combination reached 71.9%.
Safety monitoring during the NICO study confirmed that the adverse event profile remained manageable. Overall, the rates of serious grade 3 or 4 treatment-related adverse events did not differ substantially between patients with or without brain metastases. Health-related quality of life (HRQoL) remained stable throughout the treatment duration for most participants. Consequently, this study reinforces the feasibility of using dual-agent or single-agent immunotherapy in real-world settings. These results suggest that many patients can derive long-term survival benefits without compromising their quality of life.
In this real-world setting, both options showed activity. While clinical trials often favor the combination, this study noted that nivolumab alone provided high response rates in certain patient subgroups, though baseline characteristics between groups differed significantly.
Yes. Patients using dexamethasone for symptomatic brain metastases generally had lower survival rates compared to asymptomatic patients. This highlights the importance of managing brain disease before symptoms require high-dose corticosteroids.
According to the NICO study, there were no substantial differences in the rates of serious adverse events based on the presence of brain metastases, suggesting the treatments are equally tolerable in this population.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Gutzmer R et al. Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study. Int J Cancer. 2026 Mar 15. doi: 10.1002/ijc.70440. PMID: 41833546.
Tawbi HA et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018;379:722-730.
Long GV et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672-681.
"
The prospective German NICO study evaluated the real-world effectiveness of nivolumab and ipilimumab in patients with and without melanoma brain metastasis....
3 months ago

A retrospective study highlights the role of wearable monitoring systems in tracking COVID-19 patients, showing increased manual vital sign checks for unstable patients despite no change in overall clinical outcomes.
Today

A study on 294 women after the Kahramanmaras earthquake shows that death distress, especially death depression, significantly influences fertility intentions. Key factors include age, income, and trauma experience, highlighting the need for mental health support in post-disaster care.
Today

A multicohort study across 33 countries reveals that loneliness significantly increases the risk of cardiometabolic disease, particularly multimorbidity. The study highlights the synergistic impact of unhealthy lifestyles and low socioeconomic status on cardiovascular health in aging populations.
Today

Recent research highlights mussel-inspired catechol-amine copolyether brushes as a breakthrough in antifouling. By achieving high grafting density and maintaining chemical integrity, these coatings effectively prevent biofilm formation on medical devices, offering a substrate-independent solution for clinicians.
Today

Recent research identifies miR-335-5p as a key regulator for redifferentiating BRAF-mutant thyroid cancers. Restoring this microRNA enhances iodine uptake and inhibits EMT pathways, potentially resensitizing tumors to radioiodine and improving kinase inhibitor outcomes for refractory patients.
Today